To assess the impact of homeostatic expansion on the occurrence of acute GVHD after reduced intensity conditioning (RIC) transplantation, systemic levels of IL-7 and IL-15 and expression of their specific receptor chains were prospectively investigated in 45 fully HLAmatched allograft recipients. IL-7 and IL-15 levels peaked at four-to fivefold over pre-conditioning values. IL-7 levels were inversely correlated to absolute T-cell counts. Peak IL-15 levels positively correlated to concurrent CRP levels, but normalized earlier than IL-7. These results indicate that the kinetic course of IL-7 depends mainly on initiation of T-cell recovery, while IL-15 depends more on peri-transplant inflammation after RIC. Longer duration of the rise in IL-7 levels was associated with preservation of a normal CD4/CD8 ratio. In all, 16 (35%) patients developed grade 2-4 acute GVHD at a median of 42 days post graft, preceded by higher IL-7 levels and more downregulation of IL-7 receptor a chain on CD4 þ T cells than in patients without acute GVHD, suggesting enhanced homeostatic expansion. In multivariate analysis, IL-7 level measured on day þ 30 was the foremost predictive factor for grade 2-4 acute GVHD (P ¼ 0.002). Measurement of IL-7 level after RIC transplantation might help predict risk of subsequent acute GvHD.
Introduction
Non-myeloablative (MA), or reduced intensity conditioning (RIC), regimens before allo-SCT have emerged as an attractive modality to decrease transplant-related toxicity while preserving the graft-vs-tumor effect. Whatever the preparative regimen, the therapeutic efficacy of allo-SCT against hematologic malignancies relies primarily on the GVL effect, while differences in the incidence, clinical features and timing of onset of acute GVHD are reported after RIC compared with myeloablative regimens. [1] [2] [3] Indeed, inflammation after RIC is expected to be less than after dose-intense conditioning, which might translate into less cytokine production.
Lymphodepletion that follows preparative regimens induces homeostatic peripheral expansion (HPE) of donor T cells. 4, 5 During HPE, naı¨ve T cells are gradually induced to acquire a memory-like phenotype and heightened functions, which can promote antimalignant effects, but also tissue-damaging alloresponses. 6 The homeostatic cytokines IL-7 and IL-15 are essential driving forces for HPE. 7 Almost all mature T cells express the specific IL-7 receptor a chain (IL-7Ra). 8 Available IL-7 levels and the level of IL-7Ra expression, therefore, determine how vigorously the cell can respond to IL-7. 9 Memory CD8 T cells and natural killer (NK) cells express the highest levels of IL-2/15Rb chain, making these cells particularly responsive to IL-15. 7, [10] [11] [12] High systemic levels of IL-7 or IL-15 have been associated with aGVHD development after MA transplantation. [13] [14] [15] [16] Only one study has investigated RIC allo-SCT, but conditioning was preceded by intensive induction chemotherapy, 17 resulting in IL-7 levels twice as great as after MA conditioning. 13, 18 The association of IL-7Ra and IL-2/15Rb expression with acute GVHD has not been investigated after RIC allo-SCT. This prompted us to investigate prospectively plasma levels of IL-7 and IL-15, T-cell recovery and the expression levels of IL-7Ra and IL-2/15Rb chains after RIC allo-SCT.
Patients and methods

Study design and transplantation modalities
In all, 45 consecutive patients referred to our unit and treated with RIC allo-SCT were included with institutional ethics approval. Written informed consent was obtained from each patient in accordance with the Declaration of Helsinki. Patient and donor characteristics are summarized in Table 1 . In all, 21 patients (47%) were in CR at the time of transplantation, the others had partial response (n ¼ 13; 29%) or progressive disease (n ¼ 11; 24%). Patients received either low-dose TBI-based (78%) or BU-based (22%) conditioning regimens. Donors were fully molecular HLA-A, -B, -C, -DR and -DQ-matched siblings (60%) and unrelated donors (40%). Around half of the patients were transplanted with G-CSF-mobilized PBSC (n ¼ 23), and the remainder with BM (n ¼ 22). None of the grafts were ex-vivo T-cell depleted. No patient received donor lymphocyte infusions within the first 4 months post transplant. GVHD prophylaxis consisted of CsA (3 mg/kg/day) and shortcourse methotrexate (15 mg/m 2 on day þ 1, then 10 mg/m 2 on days þ 3 and þ 6 after transplantation). Supportive care has been previously reported and was similar during the entire study period. 19 Patients were monitored prospectively in terms of clinical complications; acute GVHD was graded as 1-4 based on standard criteria, even when its onset was delayed beyond 100 days from transplantation.
Measurement of IL-7 and IL-15 levels EDTA-anticoagulated blood samples were obtained before conditioning, on the day of transplantation before infusion of the allograft, then 7, 14, 18, 25, 30, 60 and 90 days post transplantation. Plasma was aliquoted shortly after collection and stored at À80 1C until analyzed. Highsensitivity ELISAs were used according to the manufacturer's protocol for measurement of IL-7 and IL-15 levels (IL-7 highly sensitive and IL-15 Quantikine ELISA kits, R&D systems, Minneapolis, MN, USA) with sensitivities (minimum detectable dose) of 0.1 pg/mL for IL-7 and of 2 pg/mL for IL-15, respectively. An automated turbidometric immunoassay was used for measurement of C-reactive protein (CRP) (sensitivity o1 mg/L; Tinaquant CRP; Roche Diagnostics GmbH, Mannheim, Germany).
Flow cytometry
To determine absolute numbers of CD3
þ NK cells, peripheral blood samples from day 30, 60 and 90 post graft were stained directly with fluorochrome-labeled monoclonal antibodies, using whole-blood lysis and fluorobeads in a multiparameter flow cytometry-based technique. 20 Naı¨ve, central memory and effector memory T-cell subsets were categorized within the CD4 þ and the CD8 þ pools based on the expression of CD45RA and CCchemokine receptor 7 markers. 21 The expression of IL-7Ra (CD127) and IL-2/15Rb (CD122) was evaluated in each of these subsets by determining the percentage of cells with positive staining for the receptor chain and their median fluorescence intensity. Directly conjugated antibodies and their isotype controls were from Beckman Coulter (Galway, Ireland), with the exception of the Ab to CC-chemokine receptor 7 from R&D Systems. The degree of donor chimerism was measured within CD3 þ cells obtained from the same blood draws by real-time PCR with a sensitivity o1%.
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Statistical analysis
Comparisons between groups were based on the MannWhitney U test or Kruskal-Wallis test and correlations were based on Spearman's R or Kendall's W coefficient of concordance, as appropriate. The median levels of IL-7 and IL-15 were used to stratify patients for Kaplan-Meier analyses. Differences between strata were evaluated by Log-rank tests. Multivariate analyses using Cox proportional-hazards models were performed using a P-value of 0.05 for the inclusion and exclusion of variables. All analyses were performed with SPSS software (SPSS v11.5, Chicago, IL, USA). 
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Results
Dynamics of plasma IL-7 levels, recovery of T cells and expression of IL-7Ra chain
Before conditioning (day 15), all patients had plasma levels of IL-7 within or slightly over the normal range (Table 1) . After initiation of the RIC regimen, median IL-7 levels increased around fivefold over the baseline level and remained relatively stable between day 0 and day þ 18, and then gradually returned close to baseline values by day þ 60 (Figure 1a ). The range of plateau levels among patients was broad, but upon serial analysis IL-7 levels proceeded along similar kinetic courses, irrespective of any demographic and clinical characteristics. Accordingly, plasma IL-7 levels were correlated to each other between day 0 and day þ 30 (P ¼ 0.029 by Kendall's coefficient of concordance), but neither to the pre-conditioning levels nor to the age of the recipient.
Kinetic courses of plasma IL-7 levels evolved inversely to absolute lymphocyte counts. At the time of transplantation, RIC regimens had induced a profound lymphodepletion (median of 0; range 0-1900 CD3 þ T cells/mL). A precise enumeration of peripheral blood T cells and their subsets could not be obtained in every patient until day þ 30. IL-7 levels were still elevated at this time point (median of 5.9 pg/mL, which is 2.3 times the baseline IL-7, IL-15 levels and acute GVHD after RIC-SCT S Thiant et al value), their ranges (0.5-22.8 pg/mL) and those of T-cell counts (40-2.500 CD3 þ T-cells/mL) were broad. IL-7 levels were negatively correlated with the absolute CD3 þ T-cell counts (R ¼ À0.529; P ¼ 0.001) (Figure 1a, insert) þ T cells expressed the IL-7Ra chain, while IL-7Ra expression was missing on some CD8
þ T cells with an effector memory phenotype. The median fluorescence intensity of IL-7Ra chain on naı¨ve and central memory T-cell subsets was lower than before RIC, and negatively correlated with concurrent IL-7 levels (Figure 1b) .
Dynamics of plasma IL-15 levels
Median levels of IL-15 peaked on day þ 7 at fourfold preconditioning levels and then rapidly declined (Figure 2a) . Peak levels correlated with values of each other between day 0 and day þ 15 (P ¼ 0.010) but not with baseline values. Correlations between IL-7 and IL-15 levels were significant from day þ 7 to day þ 25 (Po0.001 on days þ 7 and þ 14; P ¼ 0.022 on day þ 18; P ¼ 0.010 on day þ 25, respectively), but no longer significant by day þ 30 and later on. At variance with IL-7, there was no correlation between plasma IL-15 levels on day þ 30 and absolute CD3 þ T-cell counts (Figure 2a , insert) nor with CD4 þ and CD8 þ T-cell counts (data not shown). At this time point and later on, relatively few CD4 þ T cells expressed the IL-2/15Rb chain, while this chain was expressed by more than 50% of CD8 þ effector memory T cells. No correlation was found between IL-15 levels and either the percentage of IL-2/15Rb-positive T cells or the surface densities of IL-2/15Rb. In contrast, IL-15 levels were inversely correlated with both absolute NK cell counts (R ¼ À0.31; P ¼ 0.048) and the median fluorescence intensity of IL-2/15Rb on NK cells (R ¼ À0.40; P ¼ 0.026) (data not shown).
The kinetic courses of IL-15 and CRP were fairly similar but slightly staggered, with CRP peaking by day þ 14 while IL-15 levels were already declining (Figure 2b ). IL-15 and CRP levels were positively correlated on day þ 7 (which is the time when IL-15 reached a peak, R ¼ 0.488; P ¼ 0.013) and day þ 14 (R ¼ 0.621; Po0.001). In comparison, the correlation between IL-7 and CRP levels at the same time points reached marginal statistical significance (P ¼ 0.031 and P ¼ 0.034, respectively).
IL-7 and IL-15 levels according to acute GVHD
With a median follow-up of 368 (range 124-966) days, all 45 patients were evaluable for acute GVHD. In all, 20 recipients developed acute GVHD, of whom 16 developed grades 2-4 acute GVHD (9 after related and 7 after unrelated RIC-allo-SCT) ( Table 1) . When analyzing the significance of known/suspected risk factors for developing grades 2-4 acute GVHD, neither TBI-based vs BU-based regimens given nor pre-conditioning cytokine levels made a difference. By day þ 30, which is before the median time to onset of acute GVHD (42 days post graft, range 17-77 days), levels of IL-7 and IL-15 were both elevated (median of 6.7 and 10.2 pg/mL, respectively) in the subgroup with grade 2-4 acute GVHD (Figure 3a) . Cytokine levels were inversely correlated with time to onset of grade 2-4 acute GVHD (IL-7: R ¼ À0.334; P ¼ 0.031 and IL-15: ¼ À0.367; P ¼ 0.018). Grading of acute GVHD was marginally associated with IL-7 and IL-15 levels (R ¼ 0.30; P ¼ 0.05 and R ¼ 0.31; P ¼ 0.048, respectively). Absolute T-cell counts and subsets thereof did not statistically differ, but median fluorescence intensities of IL-7Ra were diminished in naı¨ve (P ¼ 0.029) and central memory (P ¼ 0.043) CD4 þ subsets in the subgroup of patients with grade 2-4 acute GVHD (data not shown).
After IL-7 levels on day þ 30 were dichotomized at the median, the cumulative incidence of grade 2-4 acute GVHD was verified to be significantly elevated if by day þ 30 patients had higher IL-7 and IL-15 levels IL-7, IL-15 levels and acute GVHD after RIC-SCT S Thiant et al (Figure 3b ). Using multivariate analyses, among all known/ suspected risk factors tested, an increased plasma level of IL-7 on day þ 30 was the only factor predictive of risk of grade 2-4 acute GVHD (hazard ratio: 1.221; 95% confidence interval: 1.076-1.386; P ¼ 0.002). Impact of cytokine levels on relapse was not tested, as few patients (n ¼ 8) relapsed over the study period.
Discussion
Our data confirm the prominent role of IL-7 in driving HPE and thereby alloreactive responses, including their detrimental effects through acute GVHD. Our data also show a significant correlation between IL-15 levels and systemic inflammation as assessed by CRP levels, while IL-7 levels were inversely correlated with T-cell counts. Plasma IL-7 level by day þ 30 was confirmed to be the primary factor significantly associated with incidence and severity of acute GVHD.
Although we acknowledge a relatively limited number of patients and a higher proportion of BM grafts than in most cohorts, all patients studied were given unmanipulated allografts with 10/10 HLA-match and the same post graft immunosuppression. With a median of 45.9 mg/L, peak values of CRP were 2.5 times less than those of our MA allo-SCT cohort 13 (123.7 mg/L, our unpublished data), as already shown by others. 23 Compared with more aggressive MA regimens, limited host tissue damage and, therefore, less inflammation and associated 'cytokine storm' are expected after RIC. CRP levels were found to be directly correlated to peak IL-15 levels, but weakly to IL-7 levels. This suggests that RIC regimens induce an acute inflammatory environment sufficient to enhance IL-15 production, as DCs and macrophages, which are key producers, can respond to proinflammatory stimuli by enhancing their production of IL-15. 7 In line with this hypothesis, others have shown that systemic levels of IL-12, a proinflammatory cytokine mainly produced by myeloid cells, are elevated from day À7 to 1 month after RIC-allo-SCT. 24 Conversely, IL-7 is primarily produced by stromal cells, and its production is not thought to be substantially affected by extrinsic stimuli. 7, 9 IL-7 levels evolved inversely to absolute T-cell counts, confirming previous reports that investigated MA preparation 13 or a dose-intense chemotherapy, given just before RIC. 17 Specifically, systemic IL-7 values were positively correlated with absolute T-cell counts by day þ 30, while IL-7, IL-15 levels and acute GVHD after RIC-SCT S Thiant et al being inversely correlated with the density of IL-7Ra on the surface of CD4 þ and CD8 þ cells. These results agree well with the current model that lymphodepletion increases the bioavailability of IL-7 by reducing its consumption, 7, 9 whereupon IL-7 induces responding T cells to downregulate the IL-7Ra chain. 8 The preserved CD4/CD8 ratio from day þ 30 onwards together with the memory-type phenotype of most circulating CD4 þ and CD8 þ cells are consistent with the ability of IL-7 to induce a dosedependent increase in circulating CD4 þ and CD8 þ T cells. 25 Conversely, we found no significant correlation between IL-15 levels and concurrent T-cell counts. Although both CD8
þ T cells and NK cells are particularly responsive to IL-15, 7, [10] [11] [12] NK cells recover faster than T cells after HLA-matched RIC-allo-SCT, 12, 26, 27 which agrees with the negative correlation obtained in this study between IL-15 levels and both NK cell counts, and their downregulated expression of the IL-2/15Rb. Together with declining systemic inflammation, IL-15 consumption by expanding NK cells might explain why systemic levels of the cytokine normalize earlier than those of IL-7.
Overall, when these results were compared with those from our MA allo-SCT patients, 13 the kinetic course and peak levels of IL-7 were fairly similar (by day þ 7 medians of 9.3 pg/mL in this series vs 11.9 pg/mL after MA conditioning 13 ). However, peak levels of IL-15 by day þ 7 were lower after RIC (median of 24.4 pg/mL vs 32.7 pg/mL 12 ). At the time of transplantation, lymphodepletion was virtually as profound after RIC as after MA regimens (with null median counts of CD3 þ T cells in our two cohorts), as even the mildest fludarabine-based regimen has strong lymphodepleting effects. 28 However, initial T-cell recovery was associated with a preserved CD4/CD8 ratio in the current study, unlike the persisting reversal of the CD4/CD8 ratio observed in our MA allo-SCT patients. 29 Altogether, these differences between the two preparative regimens are consistent with the strong dependence of naı¨ve T cells on IL-7, while IL-15 preferentially stimulates memory CD8 þ T-cell expansion, 7,9-11 and, thus, more IL-15 following MA regimens could induce a more disproportionate accumulation of CD8 þ T cells following MA transplantation. Higher plasma levels of IL-7 and IL-15 on day þ 30 preceded the development of acute GVHD. We have no data on systemic levels of IL-12, which have been associated with acute GVHD following RIC-allo-SCT 24 contrary to another study that found no association. 30 Multiple proportional hazards analysis confirmed the association of day þ 30 IL-7 levels with the risk of developing grades 2-4 acute GVHD. As pre-conditioning levels did not differ, the direct relationship between heightened IL-7 levels and subsequent acute GVHD is likely related to HPE being driven predominantly by this cytokine, with less contribution of IL-15 than following MA conditioning. The prominent role of IL-7 is also suggested by significantly more downregulation of IL-7Ra in naı¨ve and central memory CD4
þ T cells before patients went on to develop grade 2-4 acute GVHD. IL-7 is critical for driving naı¨ve and central memory T-cell expansion when coupled with recognition of peptide/MHC complexes. 31 High systemic IL-7 levels may, therefore, potentiate alloresponses of the donor T cells against disparate histocompatibility Ags, even more so that IL-7 does not induce a disproportionate expansion of regulatory T cells in humans. 23, 32 Experimentally, T cells that have undergone HPE develop augmented alloimmune responses, 33 and clinically, lymphodepletion followed by donor lymphocyte infusion induces more acute GVHD than in T-cell replete recipients. 34 We are aware of a single report on the association of serum IL-7 levels with acute GVHD after RIC transplantation, 17 but in this study all 31 patients were given up to three cycles of intense induction chemotherapy before RIC, and ensuing peak levels of IL-7 were much higher than those commonly observed after MA conditioning. 13, 18 Generalizability of the predictive value of increased systemic levels of homeostatic cytokines needed to be tested after more commonly used RIC regimens, as in experimental models, the impact of IL-7 on the severity of acute GVHD is modulated by the intensity of the conditioning regimen. 35 The present results extend evidence reported by us in the setting of MA transplantation, 13 but the time when IL-7 levels appeared to be predictive was later after RIC (day þ 30) than after MA regimen (day þ 15), in agreement with the later development of acute GVHD with RIC allo-SCT.
1,2 The present study and other reports 13, 17 showing that higher IL-7 levels predate the onset of acute GVHD, and thus, raises a possible limitation of the therapeutic administration of recombinant human IL-7 aiming at improving T-cell reconstitution following lymphopenia 25, 32, 36 in the case of allo-SCT recipients.
In conclusion, this longitudinal study indicates that the kinetic course of IL-7 reflects lymphodepletion and then cytokine consumption by the expanding cells after both MA and RIC regimens, while IL-15 production is lessened after RIC in correlation with lower systemic inflammatory biomarker levels. With acceptable regimen-related toxicities, RIC has allowed application of allo-SCT to a broader range of patients, but significant concerns remain over the morbidity caused by acute GVHD. Preventing and predicting the development of acute GVHD remains challenging. This prospective study demonstrates that determination of plasma levels of IL-7 might help predict risk of subsequent acute GVHD and allow initiation of individualized pre-emptive treatment.
